Inhibition of NLRP3 with therapies like MCC950 and PHLDA1 (pleckstrin homology-like domain family A member 1) also improved intestinal inflammation and survival in experimental NEC (82, 85). Here, NLRP3 is linked to necrotizing enterocolitis.